Abstract:Introduction: Two types of clinical resistance mutations, the C481S mutation, and BTK loss-of-activity mutations, have been identified to covalent (ibrutinib, acalabrutinib, and zanubrutinib) and non-covalent BTK inhibitors (pirtobrutinib). A safe and effective drug to treat patients who relapsed or were refractory to BTK inhibitor treatment is urgently needed. DZD8586 was designed to inhibit both BTK-dependent and BTK-independent BCR signaling pathways, with full blood-brain barrier (BBB) penetration. In the ongoing phase I/II studies (TAI-SHAN1, CTR20220558), DZD8586 demonstrated reasonable pharmacokinetic (PK) properties, safety profiles and preliminary anti-tumor activities in patients with relapsed or refractory (r/r) B-cell malignancies. Methods: The anti-tumor activities of DZD8586 were evaluated in pre-clinical cell and animal models driven by wildtype as well as various mutant BTKs. A healthy volunteer clinical study (TAI-SHAN2, NCT05176873) was conducted to investigate PK, pharmacodynamics (PD), and the safety of DZD8586, offering insight into the drug mechanism of action. The ongoing TAI-SHAN1 study in patients included dose escalation and extension cohorts. Patients with r/r B-NHL who failed systemic therapy were enrolled to determine its recommended phase II dose (RP2D). Different subtypes of B-cell Non-Hodgkin Lymphoma, including chronic lymphocytic leukemia (CLL) who failed BTK inhibitor treatment, central nervous system lymphoma (CNSL), follicular lymphoma (FL), marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL), are eligible. PD biomarkers were assessed. Results: DZD8586 showed equal potencies against wildtype and C481S mutant BTKs, as well as BTK mutations resistant to pirtobrutinib. In healthy subjects, exposure of DZD8586 increased approximately in a dose-proportional manner from 20 mg to 180 mg. Similar PK characteristics were observed between patients and healthy subjects with a half-life of ∼20 h. At the doses of ≥25 mg, near complete inhibition of pBTK was observed. A multinational dose escalation is ongoing. Patient characteristics: histological subtypes: FL, DLBCL, MZL, and MCL; median prior systemic therapies (range): 3 lines (2–6). Preliminary anti-tumor efficacies were observed in multiple B-NHL subtypes starting at 25 mg once daily. No patients experienced ≥ grade 3 treatment-related adverse events, per investigators’ assessment. Conclusion: DZD8586 is a promising investigational drug which could overcome BTK-dependent and BTK-independent resistance. In the ongoing clinical study, DZD8586 showed good safety profile and encouraging anti-tumor efficacy in heavily pre-treated r/r B-NHL patients. The updated data will be presented at the conference. Encore Abstract - previously submitted to ASCO 2023 Keyword: Molecular Targeted Therapies Conflicts of interests pertinent to the abstract Y. Bai Employment or leadership position: Dizal Pharmaceutical K. Fang Employment or leadership position: Dizal Pharmaceutical

Treatment of b‐cell malignancies with dzd8586 through overcoming both btk‐dependent and btk‐independent resistance